A transgender woman waited eight months for a cancer diagnosis while doctors focused on her HIV status and her transition instead of the tumor growing inside her.
Quick Take
- Major medical groups say cancer screening should follow the organs a person has, not their gender identity.
- Studies show transgender adults get screened for breast and cervical cancer far less often than cisgender patients.
- A Mayo Clinic discussion detailed a patient’s eight-month diagnostic delay tied to assumptions about her identity.
- Discrimination, gendered paperwork, and gaps in provider training remain the biggest obstacles to closing the gap.
The Anatomy Rule Doctors Now Follow
The American College of Obstetricians and Gynecologists says any organ that needs screening should get screened, no matter a patient’s gender identity. Their 2021 guidance also admits there is not enough data yet to know if transgender people face higher overall cancer risk. That single rule cuts through a lot of confusion. A transgender man who still has a cervix needs cervical screening. A transgender woman who has not had certain surgeries may still need prostate checks.
The University of California, San Francisco built its transgender care guidelines around the same idea. Doctors should run organ-based cancer screening for every patient, matching standard guidelines to whatever body parts are present, regardless of hormone use. This approach makes sense. It treats biology as biology while still respecting how a patient wants to be addressed and cared for.
That standard exists because the alternative failed patients for years. Guidelines built around assumed gender, rather than actual anatomy, left real organs unscreened. Doctors and researchers pushed for anatomy-based rules precisely because ignoring a body part someone still has is how cancers get missed.
A Patient’s Eight-Month Wait
Mia Inez Adams described her own experience during a Mayo Clinic discussion on cancer prevention in gender-diverse communities. Her cancer diagnosis took eight months longer than it should have because providers kept focusing on her HIV status and her transgender identity rather than her actual symptoms. She also underwent repeated, unnecessary pregnancy tests and faced assumptions about her sex life. At one imaging center, a “women only” intake form outed her transgender status on paperwork in front of staff, causing embarrassment for everyone involved.
Dr. Elizabeth Cathcart-Rake, who spoke alongside Adams, said screening should be personalized around the organs a patient has and their individual risk factors, not their identity category. She also named the real barriers standing in the way: past bad experiences with the healthcare system, discrimination, dysphoria made worse by screening procedures themselves, cost, and a basic lack of education among both patients and clinicians.
Why Screening Rates Lag So Far Behind
The numbers back up the concern. One study found transgender patients were screened for cervical cancer at 56 percent compared to 72 percent for cisgender patients, and for breast cancer at 33 percent versus 65 percent. Those gaps are not small. They represent thousands of missed mammograms and Pap tests that could catch cancer early, when it is most treatable.
A 2024 review pointed to discrimination, fear, and mistrust as direct drivers of reduced screening, and identified a lack of clinician knowledge about transgender patients as the single biggest factor behind cancelled visits and no-shows in one patient registry comparison. Doctors simply were not trained on how to talk to, examine, or refer these patients properly, and patients noticed.
Administrative systems add another layer of friction. A 2026 systematic review found many screening programs still rely on legal sex markers instead of actual anatomy, meaning non-inclusive medical records and thin provider training keep dragging down participation. Forms that assume a binary gender, or lump patients into “men” and “women” categories, do real damage. One cancer education commentary noted that materials referencing only “men with prostate cancer” or “women with uterine cancer” make transgender and intersex patients invisible, and that misgendering itself creates more barriers to care and worsens mental health outcomes.
Closing the Gap Without Compromising Standards
None of this requires abandoning medical rigor for political sensitivity. It requires the opposite: sticking closely to biology. Screen the organs that are present. Track family history and personal risk factors the same way doctors do for every other patient. Train staff to ask direct, respectful questions instead of making assumptions based on a chart’s gender marker.
The fix is not complicated, even if the rollout has been slow. Update intake forms so they ask about organs, not just gender category. Train frontline staff and physicians on basic transgender health literacy so knowledge gaps stop driving missed appointments. Keep screening anchored to anatomy and risk, the standard nearly every major medical body already endorses. That combination protects patients without diluting clinical standards one bit.
Sources:
youtube.com, ascopubs.org, academic.oup.com, acog.org, pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov
